Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CCKBR | P32239 | 1/20 | 0.30 |
| ▸ | XIAP | P98170 | 1/20 | 0.30 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26962215 | 0.91 | NPY1R (0.33) | POLBMAPTNPY1RKDM4DCCKBR | |
| SCHEMBL26961637 | 0.90 | NPY1R (0.34) | POLBMAPTNPY1RCCKBRXIAP | |
| SCHEMBL26961979 | 0.89 | NPY1R (0.31) | POLBMAPTNPY1R | |
| SCHEMBL26961707 | 0.88 | CCR1 (0.33) | NPY1RKDM4DXIAP | |
| SCHEMBL26961680 | 0.88 | CCKBR (0.34) | POLBMAPTNPY1RKDM4DCCKBR | |
| SCHEMBL26961678 | 0.88 | CNR2 (0.34) | POLBMAPTNPY1RKDM4DCCKBR | |
| SCHEMBL26962064 | 0.86 | NPY1R (0.33) | POLBMAPTNPY1RKDM4DCCKBR | |
| SCHEMBL26961956 | 0.86 | NPY1R (0.33) | POLBMAPTNPY1RKDM4DCCKBR | |
| SCHEMBL26962042 | 0.85 | DRD2 (0.34) | POLBMAPTNPY1RKDM4DCCKBR | |
| SCHEMBL26962251 | 0.85 | NPY1R (0.32) | POLBMAPTNPY1RKDM4DCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | disclosed |